BioSpace News Archive

ImmunoGen Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has advised that a new single-arm study in platinum-resistant ovarian cancer could support accelerated approval for mirvetuximab soravtansine

The European Investment Bank (EIB) and BioNTech SE (NASDAQ: BNTX, “BioNTech” or “the Company”) announced today the signing of a contract which provides financing of €50 million to BioNTech SE, an international clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases.

Bio-Techne Corporation (NASDAQ:TECH) today announced that the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to its Exosome Diagnostics (ExosomeDx) laboratory based on results of a recent on-site inspection as part of the CAP’s Accreditation Program.

Michael J. Biercuk, founder and CEO of Q-CTRL, will describe how quantum sensors may provide exceptional new capabilities to the warfighter at the Office of Naval Research (ONR) on Jan. 13, 2020, as part of the ONR’s 2020 Distinguished Lecture Series.

Prasco announced today the launch of the authorized generic of NuvaRing® (etonogestrel/ethinyl estradiol vaginal ring).

Bausch Health Companies Inc. announced that it has launched an offering of a combined $1,250,000,000 aggregate principal amount of new senior notes due 2028 and new senior notes due 2030.

Herantis Pharma Plc announced that patient recruitment in the Company’s Phase 2 clinical trial AdeLE has been completed.

Guido Guidi elected new Chairman of the Board of Directors and Robert Karsunky elected new Chairman of the Audit Committee and Board of Directors Member

Latex exposure could be detrimental to a horse’s respiratory health. That’s the surprising discovery from Morris Animal Foundation-funded research at the Royal Agricultural University and University of Nottingham.

The Ensign Group, Inc. announced that it has declared a quarterly cash dividend of $0.05 per share of Ensign common stock, payable on or before January 31, 2020, to shareholders of record as of December 31, 2019.